ライフサイエンスコーパス: hysterectomy

1 tomy, reflux surgery, bariatric surgery, and hysterectomy).

2 nonbariatric surgery (i.e., cholecystectomy, hysterectomy).

3 mortality or major morbidity (eclampsia and hysterectomy).

4 were scheduled to have a type 2 or 3 radical hysterectomy.

5 0%) had a reoperation within 30 days after a hysterectomy.

6 s, and blood transfusion within 30 days of a hysterectomy.

7 inal pelvic organ prolapse following vaginal hysterectomy.

8 ectomy, partial colectomy, appendectomy, and hysterectomy.

9 c subtypes in BRCA+ women after RRSO without hysterectomy.

10 nderwent RRSO without a prior or concomitant hysterectomy.

11 for 20 years; this was stopped in 2013 after hysterectomy.

12 Data were collected from 62 cases of hysterectomy.

13 our samples were obtained at recruitment and hysterectomy.

14 n major procedure for women in the U.S., the hysterectomy.

15 ociations between PFC levels and the rate of hysterectomy.

16 tes, aged 50 to 79 years, who did not have a hysterectomy.

17 ta previa and accreta, and consequent gravid hysterectomy.

18 uterine fibroids and did not want to undergo hysterectomy.

19 tions in postmenopausal women who have had a hysterectomy.

20 associated with increased chance of radical hysterectomy.

21 , or its costs compared with other routes of hysterectomy.

22 the internal os at MR imaging needed radical hysterectomy.

23 uterine or vaginal vault prolapse following hysterectomy.

24 0-$2349) more per case than for laparoscopic hysterectomy.

25 tomy and 1,437 (58.3%) who underwent robotic hysterectomy.

26 n and bleeding, and are the leading cause of hysterectomy.

27 ut increased cost compared with laparoscopic hysterectomy.

28 ge, race, breast cancer risk, and history of hysterectomy.

29 lization only or partial ovariectomy without hysterectomy.

30 emale genital tract and the leading cause of hysterectomy.

31 l are similar for all the methods of radical hysterectomy.

32 al women with endometrial cancer who undergo hysterectomy.

33 women with endometrial cancer who underwent hysterectomy.

34 ecause of previous colectomy, mastectomy, or hysterectomy.

35 ated, stratifying by study, age, parity, and hysterectomy.

36 s of the smooth muscle, are a major cause of hysterectomy.

37 incidence in postmenopausal women with prior hysterectomy.

38 o receive open or minimally invasive radical hysterectomy.

39 tions in postmenopausal women who have had a hysterectomy.

40 esidual confounding, such as the reasons for hysterectomy.

41 rectomy, and 1458 (19.0%) had a laparoscopic hysterectomy.

42 for most postmenopausal women who have had a hysterectomy.

43 sted hysterectomy accounted for 22.4% of all hysterectomies.

44 morbidities, and most common indication for hysterectomies.

45 ttraction to the use of robotics for radical hysterectomies.

46 ternal deaths, 2692 eclampsia cases, and 681 hysterectomies.

47 appendectomy 0.58% vs. 0.35%, P < 0.001; and hysterectomy 0.89% vs. 0.54%, P < 0.001).

48 n across operations (Pearson rho: intestinal-hysterectomy = 0.50, intestinal-endovascular = 0.36, hys

49 .001), colectomy (9.3% vs 15.0%; P < .001), hysterectomy (1.8% vs 3.9%; P < .001), and radical prost

50 inal resection (6.5 vs 5.7 d, P < 0.001) and hysterectomy (1.9 vs 1.7 d, P < 0.001), but not endovasc

51 (95% CI, 0.85-0.90) after hysterectomy vs no hysterectomy, 1.63 (95% CI, 1.52-1.75) after any vs no H

52 (18.1%), ventral hernia repair (16.7%), and hysterectomy (13.4%).

53 The median WTO wait time was higher for hysterectomy (21.6 weeks) than for UAE or MR imaging-gui

54 sted hysterectomy compared with laparoscopic hysterectomy (23.7% v 19.5%; P = .03).

55 ncluded women, 3714 (48.3%) had an abdominal hysterectomy, 2513 (32.7%) had a vaginal hysterectomy, a

56 tomy (25.8%), ventral hernia repair (26.5%), hysterectomy (28.8%), arthroplasty (18.8%), and lower ex

57 At hysterectomy, 32 patients had uterine corpus cancer and

58 imilar for robotic-assisted and laparoscopic hysterectomy (5.5% vs 5.3%; relative risk [RR], 1.03; 95

59 the trial involving 10 739 women with prior hysterectomy, 5310 were randomized to receive 0.625 mg/d

60 749]; laparoscopic cholecystectomy [82 372]; hysterectomy [67 452]; total knee replacement [42 313];

61 uded 62 patients who had undergone abdominal hysterectomy, 74 who had undergone UAE, and 61 who had u

62 ndectomy (23%), cholecystectomy (16.4%), and hysterectomy (8.2%).

63 surgical window between cancer diagnosis and hysterectomy according to patient preference.

64 erectomy was performed, robotically assisted hysterectomy accounted for 22.4% of all hysterectomies.

65 tality compared with supracervical abdominal hysterectomy (aHR, 3.64, 95% CI, 1.50 to 8.86; adjusted

66 Compared with hysterectomy alone, hysterectomy with BSO was not associ

67 Six women had hysterectomies and two women died.

68 ing 1,027 (41.7%) who underwent laparoscopic hysterectomy and 1,437 (58.3%) who underwent robotic hys

69 luding 4,139 (65.7%) who underwent abdominal hysterectomy and 2,165 (34.3%) who underwent minimally i

70 were ineligible because they had undergone a hysterectomy and 2271 because their endometrial thicknes

71 omyomata (UL) are the primary indication for hysterectomy and are 2-3 times more common in black than

72 cologic cancers associated with prophylactic hysterectomy and bilateral salpingo-oophorectomy in wome

73 e tumour debulking including total abdominal hysterectomy and bilateral salpingo-oophorectomy, and ad

74 Standard treatment consists of primary hysterectomy and bilateral salpingo-oophorectomy, often

75 of mid-endometrial samples obtained through hysterectomy and compared them with those of the cervix,

76 iation between the use of minimally invasive hysterectomy and either overall (HR, 0.89; 95% CI, 0.75

77 mined the relationship between premenopausal hysterectomy and EOC in African-American women and explo

78 Although the inverse association between hysterectomy and epithelial ovarian cancer (EOC) was con

79 Women aged 50-79 years who had undergone hysterectomy and had expected 3-year survival and mammog

80 k of diabetes after stratification by age at hysterectomy and hormone therapy status.

81 omectomy is not necessarily less morbid than hysterectomy and may have a greater failure rate than UA

82 vestigated the associations of premenopausal hysterectomy and oophorectomy with breast cancer risk.

83 ation-based analysis to compare laparoscopic hysterectomy and robotic hysterectomy for endometrial ca

84 could increase by approximately 4 years with hysterectomy and salpingo-oophorectomy and adherence to

85 women who underwent supracervical abdominal hysterectomy and total abdominal hysterectomy (TAH), whi

86 sit (the first visit after the date of NM or hysterectomy) and after index visit until the end of fol

87 es during 8404 intestinal resections, 22,854 hysterectomies, and 1471 abdominopelvic endovascular pro

88 34.2%) partial nephrectomies, 14 047 (10.4%) hysterectomies, and 1782 (6.5%) oophorectomies.

89 appendectomy, 12.1% for colectomy, 2.8% for hysterectomy, and 1.7% for prostatectomy.

90 nal hysterectomy, 2513 (32.7%) had a vaginal hysterectomy, and 1458 (19.0%) had a laparoscopic hyster

91 e obtained on patients undergoing colectomy, hysterectomy, and knee and hip replacement procedures.

92 ome was at least one of eclampsia, emergency hysterectomy, and maternal death.

93 PFCs were positively associated with rate of hysterectomy, and time since natural menopause was posit

94 controls) who provided data on ovariectomy, hysterectomy, and tubal sterilization during in-person i

95 or treatment for cervical dysplasia, had no hysterectomy, and were not pregnancy at the time of recr

96 hrectomy; 8060, partial nephrectomy; 134985, hysterectomy; and 27445, oophorectomy.

97 Varying rates of hysterectomy are a potentially important contributor to

98 Robotic sacrocolpopexy and hysterectomy are most commonly described, but the use of

99 1083 women women who underwent RRSO without hysterectomy at a median age 45.6 (IQR: 40.9 - 52.5), 8

100 en who underwent bilateral oophorectomy with hysterectomy at age </= 40 years had significantly reduc

101 d pathology reports from women who underwent hysterectomy at our institution for endometrial or endoc

102 when discussing the advantages and risks of hysterectomy at the time of RRSO in BRCA1+ women.

103 31, 2012, and underwent a benign, nongravid hysterectomy between January 1, 1996, and December 31, 2

104 dy was to determine the associations between hysterectomy, bilateral salpingo-oophorectomy (BSO), and

105 Total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and pelvi

106 ent primary surgical cytoreduction including hysterectomy, bilateral salpingo-oophorectomy, appendect

107 selected cardiac, hip/knee arthroplasty, and hysterectomy cases.

108 Vaginal delivery, hysterectomy, chronic straining, normal ageing, and abno

109 es: cesarean section, vaginal, and abdominal hysterectomy, colon, laminectomy, and spinal fusion surg

110 th, and cost for women who underwent robotic hysterectomy compared with both abdominal and laparoscop

111 ication rate was higher after robot-assisted hysterectomy compared with laparoscopic hysterectomy (23

112 er in BRCA+ women who underwent RRSO without hysterectomy compared with rates expected from the Surve

113 dometrial cancer, the use of total abdominal hysterectomy compared with total laparoscopic hysterecto

114 rious sequelae (eg, amniotic fluid embolism, hysterectomy), complications requiring intensive care un

115 Hysterectomy-corrected age-standardized uterine corpus c

116 Hysterectomy-corrected incidence rates of uterine corpus

117 Here, we evaluated recent trends in hysterectomy-corrected rates by race and ethnicity and h

118 Hysterectomy-corrected uterine corpus cancer incidence i

119 ective surgical or interventional treatment (hysterectomy, curettage, ovary excision, or excision of

120 sis with clinical censoring information (ie, hysterectomy, death, or left the health plan) on all coh

121 The rates of abdominal hysterectomy decreased both in hospitals where robotic-a

122 ibroids is surgical removal by myomectomy or hysterectomy, depending in part on the desire for future

123 evidence of uterine AVM managed by abdominal hysterectomy, describing the imaging features on ultraso

124 Minimally invasive hysterectomy does not appear to compromise long-term sur

125 CGIN); if all or nearly all women had reflex hysterectomy done soon after initial treatment; if women

126 years old and had not undergone menopause or hysterectomy during followup.

127 tomy = 0.50, intestinal-endovascular = 0.36, hysterectomy-endovascular = 0.54, all P < 0.05).

128 Premenopausal hysterectomy, even without ovary removal, may reduce the

129 teral oophorectomy is often performed during hysterectomy for benign conditions and can reduce breast

130 Although robotically assisted hysterectomy for benign gynecologic conditions has been

131 07 and 2010, the use of robotically assisted hysterectomy for benign gynecologic disorders increased

132 ompare laparoscopic hysterectomy and robotic hysterectomy for endometrial cancer.

133 al oncologists should recommend open radical hysterectomy for patients with early stage cervical canc

134 sue from the cervices of 99 women undergoing hysterectomy for reasons unrelated to epithelial abnorma

135 the potential benefits of minimally invasive hysterectomy for uterine cancer, population-level data d

136 ese findings support the use of laparoscopic hysterectomy for women with stage I endometrial cancer.

137 second branch of the WHI in women with prior hysterectomy found an even stronger correlation between

138 ith stage I-III uterine cancer who underwent hysterectomy from 2006 to 2011.

139 usal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly a

140 me was lower in the hysteropexy group vs the hysterectomy group (111.5 [39.7] min vs 156.7 [43.9] min

141 309 women in the laparoscopic supracervical hysterectomy group and 11 (4%) of 307 women in the endom

142 Adverse events in the hysteropexy vs hysterectomy groups included mesh exposure (8% vs 0%), u

143 with women without hysterectomy, women with hysterectomy had a significantly higher risk of diabetes

144 At baseline, women with either type of hysterectomy had less favorable values for CVD risk fact

145 Robotically assisted and laparoscopic hysterectomy had similar morbidity profiles, but the use

146 ng tubal ligation, oophorectomy, and partial hysterectomy have been demonstrated using current commer

147 d equine estrogens alone in women with prior hysterectomy (hazard ratio, 1.17; CI, 1.00-1.36; P=0.045

148 0.001; appendectomy HR 1.45, P < 0.001; and hysterectomy HR 1.16, P < 0.001).

149 y increased from 0.5% in 2007 to 9.5% of all hysterectomies in 2010.

150 ich is less invasive but ultimately leads to hysterectomy in 20% of women.

151 agonist, accelerated GI recovery after BR or hysterectomy in 3 phase III trials.

152 There was 1 unplanned hysterectomy in each group.

153 assurance to women and their clinicians that hysterectomy in midlife is unlikely to accelerate the CV

154 igher recurrence rates than was open radical hysterectomy in patients with early stage cervical cance

155 Despite being the primary cause of hysterectomy in the United States, accounting for up to

156 omyomata (fibroids) are the leading cause of hysterectomy in the United States.

157 morbidity and are the primary indication for hysterectomy in the United States.

158 ctive age and are the primary indication for hysterectomy in the USA.

159 recorded in 560,356 participants (without a hysterectomy) in the UK Million Women Study of whom 4067

160 tients undergoing minimally invasive radical hysterectomy, including those with tumor size <= 2 cm on

161 Use of robotically assisted hysterectomy increased from 0.5% in 2007 to 9.5% of all

162 terectomy; performance of minimally invasive hysterectomy increased from 9.3% in 2006 to 61.7% in 201

163 Laparoscopic supracervical hysterectomy involves laparoscopic (keyhole) surgery to

164 Our results suggest that hysterectomy is associated with increased risk of kidney

165 tions (BRCA+ women), the role of concomitant hysterectomy is controversial.

166 Hysterectomy is effective but has more complications tha

167 Hysterectomy is possibly protective against any stroke.

168 Hysterectomy is still the most commonly performed proced

169 Laparoscopic supracervical hysterectomy is superior to endometrial ablation in term

170 orectal cancer resection, cesarean delivery, hysterectomy, knee replacement, hip replacement, and hip

171 mpared with those who had minimally invasive hysterectomy (laparoscopic and robot-assisted).

172 men who underwent laparoscopic supracervical hysterectomy/laparoscopic myomectomy (LSH/LM), a surroga

173 soring occurred at uterine cancer diagnosis, hysterectomy, last follow-up, or death.

174 ased risk of complications when undergoing a hysterectomy later in life.

175 ons, and blood transfusion when undergoing a hysterectomy later in life.

176 ale reproductive tract and primary cause for hysterectomy, leading to considerable morbidity and high

177 omy, cystectomy, esophagectomy, gastrectomy, hysterectomy, lung resection, pancreatectomy, or prostat

178 uggests that HT use among women who have had hysterectomies may negate the protective effects of hyst

179 t increased risk of diabetes associated with hysterectomy may be due to residual confounding, such as

180 Compared with women who underwent abdominal hysterectomy, minimally invasive hysterectomy was associ

181 Women who had had hysterectomies (n = 10,272) were randomly assigned to re

182 ctomy (n = 97,780), colectomy (n = 118,407), hysterectomy (n = 26,639), or radical prostatectomy (n =

183 ated equine estrogens only if they had prior hysterectomy (N=10 739).

184 Sera/FT were collected at hysterectomy (n=21).

185 g hip and knee replacement, cholecystectomy, hysterectomy, nonaccess vascular and cardiac procedures,

186 erience in both LS and RALS each performed 2 hysterectomies on the same day.

187 ctomies may negate the protective effects of hysterectomy on EOC, creating the appearance of a null o

188 risk of diabetes was similar for women with hysterectomy only and for women with hysterectomy with c

189 at first and last births, age at menopause, hysterectomy, oophorectomy, hormone therapy use, and bod

190 combined CHD compared with not having had a hysterectomy/oophorectomy (1.51; 1.34-1.71).

191 D could be explained by greater frequency of hysterectomy/oophorectomy and earlier age at surgery aft

192 were used to assess the association between hysterectomy/oophorectomy status and diabetes incidence.

193 Having had a hysterectomy/oophorectomy was associated with higher ris

194 Hysterectomy/oophorectomy was associated with higher ris

195 lvic procedures (cholecystectomy, colectomy, hysterectomy/oophorectomy, and prostatectomy) between 19

196 No women had hysterectomies or died.

197 ailable resources, and might involve radical hysterectomy or chemoradiation, or a combination of both

198 fy high-risk patients likely to need radical hysterectomy or confirm the absence of residual tumor in

199 with occult uterine sarcoma who underwent a hysterectomy or myomectomy for presumed benign indicatio

200 ncontained power morcellation at the time of hysterectomy or myomectomy is associated with increased

201 We excluded women who had hysterectomy or oophorectomy and women who did not repor

202 at menarche, age at menopause, or history of hysterectomy or oophorectomy.

203 d (1:1) to either laparoscopic supracervical hysterectomy or second generation endometrial ablation.

204 my (OR, 0.58 [95% CI, 0.55-0.61]; P < .001), hysterectomy (OR, 0.44 [95% CI, 0.37-0.53]; P < .001), a

205 otherapy (OR, 1.82; P = .0009), and previous hysterectomy (OR, 1.34; P = .0459).

206 east cancer risk, but either oophorectomy or hysterectomy, or both, and the timing of these procedure

207 omy, total nephrectomy, partial nephrectomy, hysterectomy, or oophorectomy at 1370 hospitals in the U

208 lstilbestrol by participant's mother, age at hysterectomy, or use of oral contraceptives.

209 y was $10,618 versus $8,996 for laparoscopic hysterectomy (P < .001).

210 oscopic hysterectomy versus 8.1% for robotic hysterectomy (P = .13).

211 For hysterectomy, patients at hospitals in moderately (3.75

212 165 (34.3%) who underwent minimally invasive hysterectomy; performance of minimally invasive hysterec

213 ) were less likely to perform a simultaneous hysterectomy (performed in 11.5% vs 16.5% of patients; s

214 t: A forty-year-old female with a history of hysterectomy presenting with vague abdominal pain was co

215 We estimated hysterectomy prevalence from the Behavioral Risk Factor

216 ation of these rates requires accounting for hysterectomy prevalence, which varies by race, ethnicity

217 areas were less likely to undergo a robotic hysterectomy procedure (P < .05 for all).

218 theast were more likely to undergo a robotic hysterectomy procedure, whereas black women, those witho

219 joint replacement, vascular, colorectal, and hysterectomy procedures during the period from 1 October

220 During the same time period, laparoscopic hysterectomy rates increased from 24.3% to 30.5%.

221 Women with prior hysterectomy received CEE alone (0.625 mg/d) (n = 5310)

222 Women with prior hysterectomy received oral conjugated equine estrogen (0

223 r large, prospective study, we observed that hysterectomy, regardless of oophorectomy status, was ass

224 ysterectomy compared with total laparoscopic hysterectomy resulted in equivalent disease-free surviva

225 ocolpopexy (RALS) and robot-assisted radical hysterectomy (RRH) to their conventional laparoscopic an

226 findings provide reassurance for women with hysterectomy seeking relief of climacteric symptoms in t

227 on for women without residual disease in the hysterectomy specimen and for women with grade 1 or 2 ca

228 HESCs were isolated from hysterectomy specimens from normally cycling premenopaus

229 Evidence suggests that hysterectomy status with or without bilateral oophorecto

230 ancer were calculated, stratified by age and hysterectomy status, and adjusted by area of residence,

231 lack, 2.2% Hispanic/Latina, and 3.6% other), hysterectomy status, and date of blood draw.

232 ng, alcohol, menopausal hormone therapy, and hysterectomy status, higher HF risk was observed across

233 In 48 patients who underwent hysterectomy, surgical pathologic findings were the refe

234 ctomy (TLH) is equivalent to total abdominal hysterectomy (TAH) in women with treatment-naive endomet

235 l abdominal hysterectomy and total abdominal hysterectomy (TAH), which did not involve power morcella

236 rmin-treated group, Ki-67 was 12.9% lower at hysterectomy than at recruitment (95% CI 3.7-22.1, p=0.0

237 ival is lower for minimally invasive radical hysterectomy than for open surgery, and postoperative qu

238 Black women experience higher rates of hysterectomy than other women in the United States.

239 Apart from hysterectomy, there is no consensus recommendation for r

240 Other than a prior history of hysterectomy, there was no relevant medical history.

241 We included opioid-naive patients undergoing hysterectomy, thoracic surgery, and total knee and hip a

242 ent among women who underwent hysteropexy vs hysterectomy through 48 months (adjusted hazard ratio, 0

243 To investigate whether total laparoscopic hysterectomy (TLH) is equivalent to total abdominal hyst

244 s, the readmission rate ranged from 3.8% for hysterectomy to 14.9% for lower extremity vascular bypas

245 igned 10,739 postmenopausal women with prior hysterectomy to conjugated equine estrogen (CEE; 0.625 m

246 iatric procedures, colectomy or proctectomy, hysterectomy, total hip or knee arthroplasty, ventral he

247 rgans, including the bladder, uterus or post-hysterectomy vaginal cuff, and the small or large bowel,

248 complication rate was 9.8% for laparoscopic hysterectomy versus 8.1% for robotic hysterectomy (P = .

249 oophorectomy, 0.88 (95% CI, 0.85-0.90) after hysterectomy vs no hysterectomy, 1.63 (95% CI, 1.52-1.75

250 The mean cost for robotic hysterectomy was $10,618 versus $8,996 for laparoscopic

251 dds ratio (OR) for any morbidity for robotic hysterectomy was 0.76 (95% CI, 0.56 to 1.03).

252 t abdominal hysterectomy, minimally invasive hysterectomy was associated with a lower overall complic

253 ver users of estrogen-only HT, premenopausal hysterectomy was associated with a significantly decreas

254 with placebo among 10 739 women with a prior hysterectomy was associated with statistically significa

255 Premenopausal hysterectomy was inversely associated with the odds of E

256 Hysterectomy was not associated with risk factors for CV

257 sed both in hospitals where robotic-assisted hysterectomy was performed as well as in those where it

258 dure at hospitals where robotically assisted hysterectomy was performed, robotically assisted hystere

259 ion-level review, minimally invasive radical hysterectomy was shown to be associated with worse disea

260 In a multivariable model, robotic hysterectomy was significantly more costly ($1,291; 95%

261 with placebo, among women who had a previous hysterectomy, was significantly associated with lower br

262 aims of decreased complications with robotic hysterectomy, we found similar morbidity but increased c

263 ared with placebo in women who had undergone hysterectomy, we performed computed tomography of the he

264 l costs associated with robotically assisted hysterectomy were $2189 (95% CI, $2030-$2349) more per c

265 domly assigned to laparoscopic supracervical hysterectomy were also more likely to have the best poss

266 Women who had undergone a hysterectomy were at a significantly elevated kidney can

267 Patients who underwent abdominal hysterectomy were compared with those who had minimally

268 gh patients who underwent a robotic-assisted hysterectomy were less likely to have a length of stay l

269 6,608 postmenopausal women who had not had a hysterectomy were randomized to CEE plus medroxyprogeste

270 on of 5.6 years, and 10,739 women with prior hysterectomy were randomized to conjugated equine estrog

271 739 postmenopausal women who had undergone a hysterectomy were randomized to conjugated equine estrog

272 omen allocated to laparoscopic supracervical hysterectomy were satisfied with their operation compare

273 stectomy, hernia repair, gastric bypass, and hysterectomy) who developed perioperative complications

274 t least 36 months since last menses or since hysterectomy with a follicle-stimulating hormone concent

275 VD) before and after natural menopause (NM), hysterectomy with at least 1 ovary conserved (HOC), or h

276 my with at least 1 ovary conserved (HOC), or hysterectomy with bilateral oophorectomy (HBSO).

277 though research indicates that premenopausal hysterectomy with bilateral oophorectomy decreases the r

278 th ovarian conservation, and 106 women had a hysterectomy with bilateral oophorectomy.

279 These findings suggest that prophylactic hysterectomy with bilateral salpingo-oophorectomy is an

280 Compared with hysterectomy alone, hysterectomy with BSO was not associated with additional

281 en with hysterectomy only and for women with hysterectomy with concomitant BSO.

282 We compared laparoscopic supracervical hysterectomy with endometrial ablation in women seeking

283 were restricted to women who had undergone a hysterectomy with or without an oophorectomy.

284 scular disease (CVD) leading up to and after hysterectomy with or without bilateral oophorectomy with

285 Hysterectomy with or without ovarian conservation is not

286 therapy with ERT or placebo after undergoing hysterectomy with or without pelvic and aortic nodal sam

287 Hysterectomy with ovarian conservation (OR = 0.83, 95% C

288 ad reached natural menopause, 77 women had a hysterectomy with ovarian conservation, and 106 women ha

289 ervation (OR = 0.83, 95% CI: 0.72, 0.96) and hysterectomy with partial ovary removal (OR = 0.73, 95%

290 for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not h

291 y age for cervical cancer if they have had a hysterectomy with removal of the cervix.

292 Vaginal hysterectomy with suture apical suspension is commonly p

293 ginal mesh hysteropexy compared with vaginal hysterectomy with uterosacral ligament suspension did no

294 h hysteropexy is more effective than vaginal hysterectomy with uterosacral ligament suspension.

295 xy and 90 were randomized to undergo vaginal hysterectomy with uterosacral ligament suspension.

296 nopausal surgery, bilateral oophorectomy and hysterectomy without oophorectomy were associated with l

297 60, 95% confidence interval: 0.47, 0.77; for hysterectomy without oophorectomy, multivariable-adjuste

298 ancer in black women, it remains unclear how hysterectomy without ovary removal affects risk, whether

299 Compared with women without hysterectomy, women with hysterectomy had a significantl

300 tility in women, and a common indication for hysterectomy, yet the disease remains poorly diagnosed a